These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 28251316)

  • 1. Editor's comment on "CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein".
    Hohmann S
    Mol Genet Genomics; 2017 Jun; 292(3):535-536. PubMed ID: 28251316
    [No Abstract]   [Full Text] [Related]  

  • 2. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy and Genome Editing.
    Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
    Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
    Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene editing using CRISPR-Cas9 for the treatment of lung cancer.
    Castillo A
    Colomb Med (Cali); 2016 Dec; 47(4):178-180. PubMed ID: 28293040
    [No Abstract]   [Full Text] [Related]  

  • 6. The tsunami named CRISPR/Cas9.
    Chneiweiss H
    Rev Neurol (Paris); 2018; 174(7-8):487-488. PubMed ID: 29779853
    [No Abstract]   [Full Text] [Related]  

  • 7. Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse.
    Kang XJ; Caparas CIN; Soh BS; Fan Y
    Protein Cell; 2017 Nov; 8(11):791-795. PubMed ID: 28986765
    [No Abstract]   [Full Text] [Related]  

  • 8. Counterpoint: The Potential Harms of Human Gene Editing Using CRISPR-Cas9.
    Baylis F
    Clin Chem; 2018 Mar; 64(3):489-491. PubMed ID: 29490999
    [No Abstract]   [Full Text] [Related]  

  • 9. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
    Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH
    Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient gene correction of an aberrant splice site in β-thalassaemia iPSCs by CRISPR/Cas9 and single-strand oligodeoxynucleotides.
    Xiong Z; Xie Y; Yang Y; Xue Y; Wang D; Lin S; Chen D; Lu D; He L; Song B; Yang Y; Sun X
    J Cell Mol Med; 2019 Dec; 23(12):8046-8057. PubMed ID: 31631510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing.
    Flotte TR; Gao G
    Hum Gene Ther; 2019 Dec; 30(12):1445-1446. PubMed ID: 31860398
    [No Abstract]   [Full Text] [Related]  

  • 13. Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells.
    Patsali P; Turchiano G; Papasavva P; Romito M; Loucari CC; Stephanou C; Christou S; Sitarou M; Mussolino C; Cornu TI; Antoniou MN; Lederer CW; Cathomen T; Kleanthous M
    Haematologica; 2019 Nov; 104(11):e497-e501. PubMed ID: 31004018
    [No Abstract]   [Full Text] [Related]  

  • 14. New gene editing technique CRISPR-Cas9 raises important ethical questions, says advisory body.
    Hawkes N
    BMJ; 2016 Sep; 354():i5318. PubMed ID: 27694221
    [No Abstract]   [Full Text] [Related]  

  • 15. CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations.
    Memi F; Ntokou A; Papangeli I
    Semin Perinatol; 2018 Dec; 42(8):487-500. PubMed ID: 30482590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Exclusive Interview With CRISPR.
    McConnell SC
    AMA J Ethics; 2019 Dec; 21(12):E1079-1088. PubMed ID: 31876473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein.
    Tang L; Zeng Y; Du H; Gong M; Peng J; Zhang B; Lei M; Zhao F; Wang W; Li X; Liu J
    Mol Genet Genomics; 2017 Jun; 292(3):525-533. PubMed ID: 28251317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sharpening the Scissors: Mechanistic Details of CRISPR/Cas9 Improve Functional Understanding and Inspire Future Research.
    Raper AT; Stephenson AA; Suo Z
    J Am Chem Soc; 2018 Sep; 140(36):11142-11152. PubMed ID: 30160947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene editing in clinical isolates of Candida parapsilosis using CRISPR/Cas9.
    Lombardi L; Turner SA; Zhao F; Butler G
    Sci Rep; 2017 Aug; 7(1):8051. PubMed ID: 28808289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.